Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (180)	9/27/2009 2:59:35 PM
From: John McCarthy	Read Replies (1) \| Respond to of 421

P#4 - pSivida Ltd. Reports Operating Results (10-K) gurufocus.com gurufocus.com SEVERE EDIT - SELECTION - REARRANGEMENT Our portfolio of products and product candidates includes: Retisert Posterior uveitis FDA-approved; commercialized since 2005 Bausch & Lomb Vitrasert CMV retinitis FDA-approved; commercialized since 1996 Bausch & Lomb Iluvien Diabetic macular edema (DME) Phase III clinical trials; NDA filing planned early 2010 Alimera Iluvien Wet age-related macular degeneration (Wet AMD) Investigator-sponsored pilot clinical trial Alimera Iluvien Dry age-related macular degeneration (Dry AMD) Investigator-sponsored pilot clinical trial Alimera Iluvien Retinal vein occlusion Investigator-sponsored pilot clinical trial Alimera BrachySil Pancreatic cancer Phase II clinical trials Durasert Glaucoma Pre-clinical trials Durasert Retinitis pigmentosa Pre-clinical trials BioSilicon Retinal vein occlusion Pre-clinical trials